Gitt, Anselm K.
Rieber, Johannes
Hambrecht, Rainer
Brachmann, Johannes
Graf, Kristof
Horack, Martin
Karmann, Barbara
Vyas, Ami
Lautsch, Dominik
Ambegaonkar, Baishali
Brudi, Philippe
Funding for this research was provided by:
Merck
Article History
Received: 2 February 2018
Accepted: 23 July 2018
First Online: 3 September 2018
Compliance with ethical guidelines
:
: D. Lautsch, B. Ambegaonkar, and P. Brudi are employees of Merck & Co., Inc., which funded the study. B. Karmann is an employee of MSD SHARP & DOHME GmbH, a subsidiary of Merck & Co., Inc. A.K. Gitt reports receipt of grants and personal fees from MSD during the conduct of the study and personal fees from Sanofi and Amgen outside the submitted work. J. Rieber received handling fees for patient inclusion from MSD during the study. M. Horack reports that his institution received funding from MSD for recruitment and biostatistics for the DYSIS registry. R. Hambrecht, J. Brachmann, K. Graf, and A. Vyas. report having no conflict of interests.
: All human studies were approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All subjects provided written informed consent prior to their inclusion in the study.